Baxter International and Cell Therapeutics, Inc. (CTI) have entered into an exclusive worldwide licensing agreement to develop and commercialize pacritinib, an investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia and certain solid tumors. Pacritinib is currently in Phase III development for patients with myelofibrosis, a chronic malignant bone marrow disorder.   Baxter and CTI will jointly commercialize pacritinib in the U.S. and Baxter ha...